Back to Search
JOHN HEILIGENSTEIN, M.D.
M.D.
Neurodevelopmental Disabilities Physician
NPI: 1962763227Individual
Specialties, Licenses & Credentials
Developmental - Behavioral Pediatrics Physician
Pediatrics — Developmental - Behavioral Pediatrics
Code: 2080P0006X
01043276A(IN)
Neurodevelopmental Disabilities PhysicianPrimary
Psychiatry & Neurology — Neurodevelopmental Disabilities
Code: 2084P0005X
01043276A(IN)
Child & Adolescent Psychiatry Physician
Psychiatry & Neurology — Child & Adolescent Psychiatry
Code: 2084P0804X
01043276A(IN)
Research & Publications (16)
An exploratory factor analysis of the children's depression rating scale-revised.
PMID 16958573·J Child Adolesc Psychopharmacol·2006
8-other
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
PMID 15801334·J Atten Disord·2004
3-trial
Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
PMID 15650497·J Child Adolesc Psychopharmacol·2004
3-trial
Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.
PMID 15502599·J Am Acad Child Adolesc Psychiatry·2004
3-trial
AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology.
PMID 15266201·J Am Acad Child Adolesc Psychiatry·2004
8-other
The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration.
PMID 15219466·Biol Psychiatry·2004
4-observational
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
PMID 14709944·J Clin Psychopharmacol·2004
3-trial
Cardiovascular effects of atomoxetine in children, adolescents, and adults.
PMID 12862507·Drug Saf·2003
6-review
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
PMID 12523874·J Clin Psychiatry·2002
3-trial
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
PMID 12456942·Pediatrics·2002
3-trial
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
PMID 12431845·Neuropsychopharmacology·2002
7-preclinical
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
PMID 12364842·J Am Acad Child Adolesc Psychiatry·2002
3-trial
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
PMID 12108801·J Am Acad Child Adolesc Psychiatry·2002
3-trial
The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.
PMID 11763002·J Clin Psychopharmacol·2001
4-observational
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.
PMID 11642475·J Child Adolesc Psychopharmacol·2001
3-trial
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
PMID 11437015·J Am Acad Child Adolesc Psychiatry·2001
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4470 BRAEDONWOOD
INDIANAPOLIS, IN 46228 - Phone
- (317) 225-1449
Quick Facts
- NPI
- 1962763227
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 16
Are you this provider?
Claim Your Profile